Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial.
In a subset of patients from the DART trial (Uganda/Zimbabwe) of antretroviral therapy monitoring strategies, treated with zidovudine/lamivudine and tenofovir, viral load was measured after 0, 24 and 48 weeks, and the pol gene of viruses from samples with a high viral load was sequenced. There was a high prevalence of mutations and resistance, especially after 48 weeks – without viral load monitoring to indicate when a change of treatment is necessary, extensive resistance is likely. 10% of baseline samples had evidence of resistant virus, probably due to undisclosed previous treatment.
14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007: Abstract 642.